Pulin Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 10-12-2024
- Paid Up Capital ₹ 0.50 M
as on 10-12-2024
- Company Age 11 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.00 M
as on 10-12-2024
- Satisfied Charges ₹ 4.13 M
as on 10-12-2024
- Revenue 15.74%
(FY 2022)
- Profit 2.42%
(FY 2022)
- Ebitda 16.57%
(FY 2022)
- Net Worth 20.31%
(FY 2022)
- Total Assets 0.94%
(FY 2022)
About Pulin Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹6.00 M. The company has closed loans amounting to ₹4.13 M, as per Ministry of Corporate Affairs (MCA) records.
Anju Patni and Nawal Patni serve as directors at the Company.
- CIN/LLPIN
U24232RJ2013PTC041811
- Company No.
041811
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Mar 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Pulin Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anju Patni  | Director | 13-Mar-2013 | Current |
| Nawal Patni | Director | 13-Mar-2013 | Current |
Financial Performance of Pulin Pharmaceuticals.
Pulin Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 15.74% increase. The company also saw a slight improvement in profitability, with a 2.42% increase in profit. The company's net worth Soared by an impressive increase of 20.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pulin Pharmaceuticals?
In 2022, Pulin Pharmaceuticals had a public holding of 0.02%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 05 Nov 2022 | ₹2.00 M | Open |
Others Creation Date: 28 Jun 2021 | ₹4.00 M | Open |
The South Indian Bank Limited Creation Date: 10 Mar 2017 | ₹4.13 M | Satisfied |
How Many Employees Work at Pulin Pharmaceuticals?
Unlock and access historical data on people associated with Pulin Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pulin Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pulin Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
